Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Research & Development (2016 - 2024)

Historic Research & Development for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q4 2024 value amounting to $10000.0.

  • NovaBay Pharmaceuticals' Research & Development rose 60000.0% to $10000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $42000.0, marking a year-over-year increase of 2352.94%. This contributed to the annual value of $42000.0 for FY2024, which is 2352.94% up from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Research & Development of $10000.0 as of Q4 2024, which was up 60000.0% from $4000.0 recorded in Q3 2024.
  • In the past 5 years, NovaBay Pharmaceuticals' Research & Development registered a high of $125000.0 during Q3 2020, and its lowest value of -$2000.0 during Q4 2023.
  • Moreover, its 5-year median value for Research & Development was $14500.0 (2021), whereas its average is $29000.0.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Research & Development soared by 72500.0% in 2022 and then tumbled by 10303.03% in 2023.
  • Over the past 5 years, NovaBay Pharmaceuticals' Research & Development (Quarter) stood at $36000.0 in 2020, then tumbled by 77.78% to $8000.0 in 2021, then surged by 725.0% to $66000.0 in 2022, then crashed by 103.03% to -$2000.0 in 2023, then skyrocketed by 600.0% to $10000.0 in 2024.
  • Its Research & Development was $10000.0 in Q4 2024, compared to $4000.0 in Q3 2024 and $9000.0 in Q2 2024.